Re: Minutes from the 2/24/16 DDI Information task force discussion (content sub group)

Why?

https://rxnav.nlm.nih.gov/InteractionAPIs.html#



On Sat, Mar 26, 2016 at 1:01 PM, Richard Boyce <rdb20@pitt.edu> wrote:

> (FYI for folks on the public-semweb-lifesci list who are not participating
> in the task force [1])
>
> Hello,
>
> Below I have pasted the minutes from the last meeting of the content
> sub-team for the DDI Minimum Information Model task force [1].  I apologize
> that I was forgot to record the meeting but I have tried to write detailed
> minutes. The full set of minutes for the task force are available [2].
>
> 1. https://sites.google.com/site/ddikrandir/home/ddi_info_model_taskforce
> 2. https://goo.gl/TKWfNN
>
> ------------
> Minutes for 2/24/2016 (Content subgroup)
>
> In Attendance : Dan Malone, Evan Draper, John Horn, Oktie Hassanzadeh,
> Richard Boyce, Sam Habiel
>
> Meeting recording: None taken (Rich forgot to start the recording, Sorry!)
>
> Meeting:
>
>    -
>
>    Brief discussion of progress on the proposed task force activities:
>
>
>
>    1.
>
>    Clarify definitions for the seven minimum information items
>    recommended by prior AHRQ drug interaction conference series
>    -
>
>       A sub-team has been working on creating definitions. Initial ideas
>       have been developed and will be discussed over the next month:
>       https://goo.gl/N0MxPd
>       -
>
>       Some questions were raised by the sub-team that were discussed
>       later during the meeting.
>
>
>
>    1.
>
>    Propose additional attributes
>    -
>
>       Depends on Activity 1
>
>
>
>    1.
>
>    Create deliverables using an interesting and non-trivial set of
>    potential drug-drug interactions:
>    -
>
>       Depends on Activities 1 and 2
>       2.
>
>    Create a foundation for further collaborative work by disseminating
>    results through an interest group note, a website, and an online discussion
>    forum
>    -
>
>       Ratnesh Sahay has created a project that will be used for advancing
>       development of the interest group note:
>       <https://github.com/W3C-HCLS/w3c-ddi>
>       https://github.com/W3C-HCLS/w3c-ddi
>       1.
>
>          A very initial outline can be seen here: <http://goo.gl/ZMU1Wm>
>          http://goo.gl/ZMU1Wm
>          2.
>
>          All persons who have participated in the calls have been listed
>          as contributors for now (in alphabetical order by first name). Please email
>          Rich Boyce with spelling corrections and the affiliation you would like (or
>          if you would like your name removed)
>          -
>
>       Scott Nelson submitted a panel proposal on 3/10 to AMIA to discuss
>       the topic of including seriousness as a minimum information item
>
>
>
>    -
>
>    Discussion of what DDI content to include in our deliverables.
>    -
>
>       Sub-team members had made progress on suggesting interacting pairs
>       based on known issues with DDI evidence and knowledge
>       -
>
>          See https://goo.gl/rYpmjt
>          -
>
>       Rich created a survey to increase the participation:
>       <https://pitt.co1.qualtrics.com/jfe/form/SV_0GPfzm7UbGDYV5X>
>       https://pitt.co1.qualtrics.com/jfe/form/SV_0GPfzm7UbGDYV5X
>       -
>
>          Survey closes EOB Wednesday 3/30
>          -
>
>       It was decided that only one or two PDDIs will be selected for each
>       category. The group agreed that, for each PDDI, a decision tree will be
>       created that provides 1) information that can help contextualize the
>       interaction depending on drug and patient factors, 2) management
>       recommendations depending on the contextualizing factors in (1), and 3)
>       evidence supporting or refuting each scientific claim made for (1)
>       -
>
>          Such decision trees have already been created by John Horn and
>          Phil Hansten for several interactions as part of Dan Malone’s AHRQ grant
>          (R21HS023826).
>          -
>
>             These can be used for the project as long as we provide
>             citation to the authors and grant.
>             -
>
>             These interactions might fit as representative for certain
>             information categories. The group agreed that, for those cases, additional
>             interactions will be chosen to provide heterogeneity
>             -
>
>    Discussion of stakeholders
>    -
>
>       The question of who the stakeholders are for the min info model
>       came up from the Standard sub-team. The content sub-team agreed that the
>       stakeholders included primarily the following:
>       -
>
>          Clinicians (doctors, nurses, pharmacists, and various
>          practitioners) who must use PDDI information to make clinical decisions
>          -
>
>          Persons who create systems that provide PDDI information to
>          clinicians in various settings (e.g., database vendors, drug information
>          editorial boards)
>          -
>
>          Organizations that provide publicly available lists of drug-drug
>          interactions (e.g., developers of RxNorm)
>          -
>
>       Clarification of this in writing is planned
>       -
>
>    Discussion of use cases:
>    -
>
>       Members of the standard sub-team had suggested using Medication
>       Reconciliation as a target use case for showing the value of the info model
>       (e.g., competency questions). Rich asked the content sub-team for comment
>       -
>
>          It was agreed that med rec is an important use case but one that
>          can probably be broken down into a number of smaller use cases depending on
>          the phase of the medication therapy process in question (e.g., ordering,
>          consulting, monitoring)
>          -
>
>       Clarification of this in writing is planned and also a focused
>       discussion at our “all team” meeting in May.
>       -
>
>    Action Items
>    -
>
>          Rich will merge the final results of the survey on suggested
>          PDDIs (
>          <https://pitt.co1.qualtrics.com/jfe/form/SV_0GPfzm7UbGDYV5X>
>          https://pitt.co1.qualtrics.com/jfe/form/SV_0GPfzm7UbGDYV5X) into
>          the google sheet ( <https://goo.gl/rYpmjt>https://goo.gl/rYpmjt)
>          -
>
>          He will then go through and highlight the PDDIs for which
>          decision trees have been created as part of Dan Malone’s AHRQ grant
>          - The next meeting will finalize the list and future meetings
>          will finalize decision trees for the chosen interactions. In parallel, the
>          standard sub-team will work on representing the chosen interactions,
>          seeking feedback as they go.
>
>
> --
> Richard D Boyce, PhD
> Assistant Professor of Biomedical Informatics
> Faculty, Center for Pharmaceutical Policy and Prescribing
> Faculty, Geriatric Pharmaceutical Outcomes and Gero-Informatics Research and Training Program
> University of Pittsburghrdb20@pitt.edu
> Office: 412-648-9219
> Twitter: @bhaapgh
>
>


-- 
Timothy W. Cook, President
Data Insights, Inc.

Received on Tuesday, 29 March 2016 06:31:04 UTC